From Discovery To Clinical Impact: How Advanced Imaging Is Transforming Drug Development
Imaging technologies are becoming integral to modern drug development, providing non-invasive, quantitative insights into drug activity, efficacy, and key biological markers. Particularly valuable in early-phase studies, imaging can inform safety and dosing decisions while helping accelerate and de-risk development pipelines. Emerging technologies, including theranostics, are expanding these capabilities across oncology, CNS, and other therapeutic areas, while collaboration among sponsors, CROs, and imaging partners remains critical to overcoming adoption challenges and maximizing their impact.
In this roundtable discussion, industry experts with hands-on experience in imaging explore:
- How and why imaging technologies have grown in scope and value to become a core element of modern drug development
- The latest technology trends and innovations shaping the imaging landscape
- The evolving importance and impact of theranostics
- Case studies demonstrating how imaging can help connect drug discovery to clinical development and accelerate decision-making
- Key challenges to broader adoption, including cost, standardization, and validation against clinical endpoints
- The importance of collaboration among sponsors, clinical CROs, and imaging/nonclinical CRO partners
Roundtable Panelists:
- Beth Gorman, Associate Director, Clinical Imaging, Regeneron
- Teruyoshi Okuda, Board Member, CMIC Pharma Science
- Rachele Rossi, Scientific Director, Vesalic
- Mike Suga, Executive Project Lead, CMIC Pharma Science
- Christopher Winkelmann, Founder, Voxelara Consulting
- Moderator: Barnaby Pickering, Managing Editor, Custom Content, Citeline
Learn more about CMIC’s noninvasive medical imaging capabilities >>
